Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia

IntroductionOlder patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effect...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Qingyang Liu, Jingjing Yang, Lei Lv, Xiawei Zhang, Meng Li, Lingmin Xu, Sai Huang, Yu Jing, Liping Dou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-02-01
Edice:	Frontiers in Immunology
Témata:	venetoclax azacitidine CACAG-VEN regimen older patients acute myeloid leukemia
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525110/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!